What's Happening?
Ori Biotech, a leader in cell and gene therapy manufacturing technology, has partnered with ImmuXell Biotech, a Shanghai-based clinical-stage cell therapy company, to dose the first patient in an investigator-initiated trial (IIT). This trial uses ImmuXell's
TCR-T cell therapy, manufactured on Ori's IRO® platform, targeting solid tumors with KRAS G12V mutations, including colorectal, pancreatic, and lung cancers. The collaboration began in December 2025, and within four months, the first patient was dosed, demonstrating the platform's ability to transition from process development to patient dosing efficiently. The partnership aims to file an IND application in China for a Phase 1 clinical trial later in 2026.
Why It's Important?
This partnership is significant as it highlights the potential of Ori's IRO® platform to revolutionize cell therapy manufacturing by improving speed, quality, and cost-effectiveness. The ability to rapidly adapt and optimize manufacturing processes without compromising safety or efficacy is crucial for advancing treatments for cancers with limited options. The collaboration also marks Ori's first venture in the Asia Pacific region, expanding its global footprint and potentially increasing access to life-saving therapies. The success of this partnership could set a new standard in cell therapy manufacturing, benefiting patients and the biotech industry.
What's Next?
Ori Biotech and ImmuXell plan to continue their collaboration by progressing the current IIT and filing an IND application in China for a Phase 1 clinical trial. The companies aim to bring the TCR-T therapy to more patients in China and further develop their ex-vivo cell therapy pipeline. Ori's IRO® platform is expected to gain more partners worldwide, with the first INDs for IRO®-manufactured products anticipated to be filed by late 2026. This ongoing development could lead to broader adoption of the platform in clinical settings, enhancing the availability of advanced therapies.
